The prevalence of non-alcoholic fatty liver disease (NAFLD) is strongly increasing and may put patients at increased risk for atherosclerotic cardiovascular disease (asCVD). Both disease phenotypes often co-occur, in the case of obesity, insulin resistance, diabetes mellitus type 2, and the metabolic syndrome. We explore the pathogenesis of NAFLD, the epidemiology of asCVD in NAFLD patients, shared drivers of both phenotypes, and factors caused by NAFLD that contribute to asCVD. Genetic studies support that NAFLD may drive asCVD through mixed hyperlipidemia. Next, we discuss the prospects of lifestyle improvement and pharmacological treatment of NAFLD for asCVD risk reduction. Finally, we point out that earlier identification of patients with NAFLD should be pursued by increasing awareness of the association of these two phenotypes and collaboration between the involved physicians.

中文翻译：

---

NAFLD 和动脉粥样硬化：同一个代谢障碍硬币的两个方面？

非酒精性脂肪性肝病 (NAFLD) 的患病率正在急剧增加，并可能使患者患动脉粥样硬化性心血管疾病 (asCVD) 的风险增加。在肥胖、胰岛素抵抗、2 型糖尿病和代谢综合征的情况下，这两种疾病表型经常同时发生。我们探讨了 NAFLD 的发病机制、NAFLD 患者中 asCVD 的流行病学、两种表型的共同驱动因素以及 NAFLD 引起的导致 asCVD 的因素。遗传研究支持 NAFLD 可能通过混合性高脂血症驱动 asCVD。接下来，我们讨论生活方式改善和 NAFLD 药物治疗以降低 asCVD 风险的前景。最后，